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The European badger (Meles meles) is a reservoir host of Mycobacterium bovis and
responsible for a proportion of the tuberculosis (TB) cases seen in cattle in the
United Kingdom and Republic of Ireland. An injectable preparation of the bacillus
Calmette-Guérin (BCG) vaccine is licensed for use in badgers in the UK and its use
forms part of the bovine TB eradication plans of England and Wales. However, there are
practical limitations to the widespread application of an injectable vaccine for badgers
and a research priority is the development of an oral vaccine deliverable to badgers in bait.
Previous studies reported the successful vaccination of badgers with oral preparations
of 108 colony forming units (CFU) of both Pasteur and Danish strains of BCG contained
within a lipid matrix composed of triglycerides of fatty acids. Protection against TB in
these studies was expressed as a reduction in the number and apparent progression
of visible lesions, and reductions in the bacterial load and dissemination of infection.
To reduce the cost of an oral vaccine and reduce the potential for environmental
contamination with BCG, it is necessary to define the minimal efficacious dose of oral
BCG for badgers. The objectives of the two studies reported here were to compare
the efficacy of BCG Danish strain in a lipid matrix with unformulated BCG given orally,
and to evaluate the efficacy of BCG Danish in a lipid matrix at a 10-fold lower dose
than previously evaluated in badgers. In the first study, both BCG unformulated and in
a lipid matrix reduced the number and apparent progression of visible lesions and the
dissemination of infection from the lung. In the second study, vaccination with BCG in
the lipid matrix at a 10-fold lower dose produced a similar outcome, but with greater
intra-group variability than seen with the higher dose in the first study. Further research
is needed before we are able to recommend a final dose of BCG for oral vaccination of
badgers against TB or to know whether oral vaccination of wild badgers with BCG will
significantly reduce transmission of the disease.
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INTRODUCTION
Tuberculosis (TB) in cattle, arising from infection with the
bacterium Mycobacterium bovis, causes substantial financial
losses to the governments of the United Kingdom, Ireland
and the cattle industry (University of Reading, 2004). In these
countries, the European badger (Meles meles) is a wildlife
reservoir of M. bovis that can spill over into cattle, frustrating
attempts to control the disease using measures focussed on cattle
alone (Brooks-Pollock et al., 2014). Controlling infection within
badger populations at risk of transmitting the disease to cattle is
difficult, expensive, and contentious, especially control by culling.
Reducing the prevalence of TB in badgers through vaccination,
and as a consequence reducing the risk of transmission of
infection to and from cattle, is part of the long-term plan to
eradicate TB from cattle in the UK and Ireland.
The BCG (bacillus Calmette-Guérin) vaccine, an attenuated
strain of M. bovis, is currently the only vaccine available for use
in badgers. It is licensed in the UK as a lyophilized preparation
for the intramuscular vaccination of badgers (BadgerBCG, 2010).
The costs associated with its purchase and the costs and practical
limitations associated with its administration limit its use in the
field (Enticott et al., 2012). The best prospect for the wide-scale
use of BCG in badgers relies on the development of an oral
presentation of BCG in a bait matrix for ingestion by badgers.
In previous studies conducted by University College Dublin,
we reported the successful vaccination of badgers with an oral
preparation of BCG contained within a protective lipid matrix
composed of triglycerides of fatty acids (Corner et al., 2010;
Murphy et al., 2014). This matrix provided a stable oral bait
for BCG vaccine (reviewed in Beltrán-Beck et al., 2014). The
Pasteur strain of BCG at an oral dose of 108 colony-forming
units (CFU) was used in the first of these studies: the Pasteur
strain was recommended by a joint WHO/FAO/OIE consultative
group in 1994 for vaccine trials in animals (World Health
Organization, 1994). Protection against TB was expressed as
fewer organs/tissues with visible lesions, a decrease in the severity
of visible lesions, fewer sites of infection, and lower bacterial load
in the lungs and thoracic lymph nodes in vaccinates compared
with controls. Danish 1331 strain is the only BCG vaccine
currently licensed in the European Union for use in humans for
immunization against TB and is available commercially from the
Staten Serum Institute, Denmark. It is also the strain of BCG used
in BadgerBCG. Basing an oral BCG badger vaccine on the Danish
1331 strain therefore would simplify licensing. When the efficacy
of these two BCG strains in lipid matrix at 108 CFU was tested
in badgers, they gave similar levels of protection (Murphy et al.,
2014).
Previous studies in mice, guinea pigs and possums showed
oral encapsulated BCG gave superior protection to unformulated
oral BCG (Clark et al., 2008). We wanted to make this
comparison in badgers. Also, in previous oral vaccine studies in
badger we used BCG at more than 10 times the injectable dose
and some excretion of BCG in feces was observed (Corner et al.,
2010). From the perspective of reducing both the cost of an oral
vaccine and the potential for environmental contamination with
BCG, we need to define the minimal efficacious dose for badgers.
Given that the effective dose of injected BCG appears to bear
no relationship to the size of the target animal—10 equivalent
human doses of BCG Danish for badgers (Lesellier et al., 2011)
compared to 0.5 equivalent human doses for cattle (Buddle et al.,
2013)—these data have to be generated empirically using badgers.
The objectives of the two vaccine efficacy studies (VES) reported
here were to compare the efficacy of BCG Danish strain in a
lipid matrix with unformulated BCG given orally (VES3) at a
dose of 108 CFU, and to evaluate the efficacy of BCG Danish in a
lipid matrix at a 10-fold lower dose than previously evaluated in
badgers (VES4).
We report that the incorporation of BCG in the lipid matrix
appears beneficial for effective oral delivery, and encouraging
results were obtained with unformulated oral BCG. In a second
study, promising results were obtained with 107 CFU BCG in
the lipid matrix but, in contrast to the first study, not with 108
CFU BCG in the lipid matrix. These studies have important
implications for the progress of work toward a reproducibly
efficacious oral vaccine against TB in badgers.
MATERIALS AND METHODS
Two separate studies were conducted to evaluate the protective
effect of different BCG oral vaccines in badgers subjected to
endobronchial challenge with virulent M. bovis; an established
model for what is primarily a respiratory disease in wild-infected
badgers. During the studies, immune responses were measured.
Clinical samples, as detailed below, were collected to look for
excretion of BCG and M. bovis. The burden of disease in the
badgers was ascertained at the end of each study on the basis of
pathology (visible lesions, histopathology) and bacteriology.
Ethics Statement
All animal procedures were covered by licenses issued by the
UK Home Office under the Animal [Scientific Procedures] Act
1986, and approved by the Animal Welfare and Ethical Review
Board at the Animal and Plant Health Agency (APHA). This
manuscript was prepared to comply with the ARRIVEGuidelines
for reporting animal research (Kilkenny et al., 2010).
Badgers
Thirty-seven wild badgers of both sexes and mixed age groups
were obtained from counties in England where the incidence
of TB in cattle and badgers was historically either very low
or absent. Three additional badgers were born in captivity at
APHA. The wild badgers were allowed to acclimatize to captivity
for a week. All animals used in experiments were confirmed
as free of TB on the basis of three negative IFNγ tests and
negative for M. bovis on culture of clinical samples (tracheal
aspirate, laryngeal swab, urine, rectal swab and feces) taken on
three separate occasions approximately 30 days apart before
enrolment into a study. Badgers were housed in isolation from
wild badgers in theNatural Environment Centre (NEC) in groups
of four to a pen, as far as possible corresponding to their original
social grouping and then transferred to a Containment Level
3 (CL3, Advisory Committee on Dangerous Pathogens) animal
facility in the same social groups. Allocation of pen groups
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to treatments was by randomisation. Twenty animals were
enrolled into each study. In VES3, the badgers were transferred
from the NEC to the ACDP CL3 facility before vaccination.
In VES4, they were moved to the CL3 facility 70 days after
vaccination (20 days in advance of the challenge). Vaccination
was conducted in summer (June-July) and the challenge in
autumn (September-October) and the studies were terminated in
December-January.
Each badger was given a unique identifier (microchip AVID
PLC, Uckfield, East Sussex) and by tattooing the last three
digits of the microchip number on the abdomen. Throughout
the studies, the badgers received dog food and peanuts daily,
occasionally chicken eggs from the APHA Specific-Pathogen-
Free hatchery, and they were free to forage in the NEC. The
badgers were examined visually on a daily basis inside wooden
sett boxes provided to them. Tap water was provided ad libitum.
CB-BCG Vaccine
A suspension of BCG Danish strain 1131 was supplied by the
Statens Serum Institute, Denmark in a solution of 1.5% (w/v)
sodium 2-aminopentanedioate (monosodium glutamate). The
vaccine [Concentrated Bulk (CB)-BCG] was stored in 100 µl
aliquots at−10.5 to−29.5◦C. At the time of use, the vaccine had
been in storage for approximately 25 weeks. The titre of CB-BCG
(Table 1) was determined from the thawed stock of vaccine on
the day of administration.
BCG-LiporaleTM Vaccine
Bacillus Calmette-Guérin (BCG) Danish strain 1131 was supplied
by Immune Solutions Ltd (ISL), University of Otago, New
Zealand in a lipid matrix. Unlike CB-BCG, the vaccine (BCG-
lipid PK/LiporaleTM) was prepared from a fresh, broth-grown
culture of BCG and stored according to standard protocol
(Aldwell et al., 2003). Stocks were frozen at−80◦C; a temperature
at which the viability of similarly prepared BCG stocks had
been found to be stable for 24 months (Frank Aldwell, personal
communication). Vaccine was prepared from frozen batches of
BCG, as follows. The BCG pellets were thawed for 30 min at
20–22◦C, re-suspended and dispersed in lipid PK (C1758; Sigma-
Aldrich, Australia Ltd) that had been warmed to 26◦C in a stirred
water bath. Lipid formulated BCG was gently mixed in 50 ml
tubes (Falcon) and allowed to cool to 22◦C. 1.0–1.2 ml volumes
were taken up into 3 ml Luer-Lock syringes (Becton Dickinson)
and capped with either blue or white Combi-lock plugs (Codan)
according to the concentration of BCG in the preparation: 2–3×
108 CFU/ml (HD, VES3, and VES4) or 107 CFU/ml (LD, VES4)
(Table 1) per ml. Capped syringes were transferred to 4◦C. These
were consigned to APHA as perishable goods (cold chain) and
maintained at <8◦C, as determined by a temperature monitor
located with the samples. On receipt at APHA, the syringes were
maintained at 4◦C until use. Additional syringes of LiporaleTM
matrix alone were supplied as negative controls. Representative
syringes containing vaccine were retained by ISL for retrospective
analysis of CFU. As LiporaleTM is intended to be both vaccine
vehicle and bait matrix, a volume of 1 ml of BCG-LiporaleTM or
LiporaleTM (placebo) was administered.
Mycobacterium bovis
The M. bovis strain used for challenge was originally isolated
from a wild badger in the UK in 1997 (isolate 74/0449/97).
It was stored as a first passage stock culture until expanded
and then stored as frozen aliquots (−80◦C). The clonality of
the culture was confirmed by demonstrating the spoligotype–
SB0140 (APHA type 9) and VNTR type (8-5-5-5-3-3.1) of 27
individual colonies (10% of those grown from a 1:1000 dilution
of a culture at approximately 105 CFU/ml). The stock vials
used for the challenge had not been passaged further. Each vial
contained approximately 107 CFU/ml viableM. bovis. On the day
of challenge, one aliquot was thawed, serially diluted in sterile
water + 0.05% (v/v) Tween 80 to contain approximately 104
CFU/ml. The last dilution to 1000 CFU/ml was made in PBS +
0.05% (v/v) Tween 80. This solution was vortexed immediately
before delivery to diminish the risk of bacterial clumping. The
titre of the challenge inoculum was determined by plating on
modified Middlebrook 7H11 agar (Gallagher and Horwill, 1977)
a sample from a syringe kept in the same conditions as those used
for challenge.
Clinical Sampling
Badgers were anesthetized once every 2 to 3 weeks by
intramuscular injection of approximately 10 mg/kg of
ketamine (Vetalar R©, Pfizer Animal Health, New York, NY,
USA), 100 µg/kg of medetomidine (Domitor R©, Pfizer Animal
Health) (Davison et al., 2007) and 100 µg/kg of butorphanol
(Torbugesic R©, Zoetis UK Ltd, Tadworth, Surrey, UK). Blood
was collected by jugular venipuncture into heparinised and
serum separation BD Vacutainer R© tubes for immunological
assays. Body weight, general condition and rectal temperature
TABLE 1 | Vaccination of badgers with BCG: number of animals in each experiment, treatment group, sex, and the vaccine and challenge doses.
Experiment Treatment group Dose of BCG (CFU) Dose of M. bovis (CFU/ml) Number of badgers Sex distribution (M, F)
VES3 CB-BCG 9.30 × 107 1.20–1.85×103 4 3M, 1F
HD BCG-LiporaleTM 1.86 × 108 8 3M, 5F
Control – 8 4M, 4F
VES4 HD BCG-LiporaleTM 3.20 × 108 0.98–1.01 × 103 4 1M, 3F
LD BCG-LiporaleTM 9.65 × 106 7 2M, 5F
Control – 8 4M, 4F
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were recorded for welfare monitoring purposes. Tracheal mucus
was collected by aspirating with a flexible urinary catheter and
dispensed into Middlebrook 7H9 broth supplemented with ADC
enrichment (BD, Oxford, UK). Laryngeal and rectal swabs were
collected and placed into 7H9 broth and PBS, respectively. Urine
was collected into sterile 15 ml plastic tubes following manual
compression of the bladder.
Vaccination and Challenge
Bacillus Calmette-Guérin (BCG) LiporaleTM and the LiporaleTM
placebo were administered to anesthetized badgers using a
syringe and catheter to the proximal region of the esophagus.
In VES3, BCG-LiporaleTM and LiporaleTM placebo were heated
to 37◦C degrees before delivery and were fully liquefied. In
VES4, the BCG-LiporaleTM and LiporaleTM placebo were heated
to 24◦C degrees before delivery and was an opalescent semi-
solid. After vaccine or placebo administration the syringe was
removed from the catheter and 10 ml of air was flushed through
the catheter to ensure that all vaccine and placebo was delivered.
After treatment, the badgers were kept in sternal recumbence
until they had recovered from anesthesia. ISL determined the
concentration of BCG in material withheld but treated in the
same way as that delivered to the APHA (Table 1).
CB-BCG was thawed and gently mixed immediately prior to
use and was administered to each badger as a 180 µl volume
deposited on the surfaces of the left and right tonsils. If CB-
BCG was to be used for widespread application it would most
likely be inside oral bait, so this smaller volume was chosen as
representative of the volume that might be used, and to achieve a
dose of 1× 108 CFU, directly comparable to the ISL lipid.
Mycobacterium bovis challenge was performed under
anesthesia 13 weeks after vaccination by endobronchial
instillation of 1 ml of M. bovis suspension per badger using
a fiberscope (Olympus URF P2 3.6 mm outside diameter, 1.8
mm inside diameter, 70 cm long), targeting the bronchus of the
right middle lobe. For each animal the M. bovis suspension was
inoculated via a sterile plastic catheter (1.5 mm diameter) and
the catheter was flushed with 1 ml PBS. Between animals, the
fiberscope was disinfected with ortho-phthalaldehyde and 70%
(v/v) ethanol then rinsed with sterile water. The used catheters
were discarded.
Table 1 shows the number and sex of animals in each
treatment group and study, and the doses of BCG vaccine and
M. bovis administered.
Bacteriology
Clinical samples (tracheal aspirate, laryngeal swab, urine and
rectal swab) were taken every 2–3 weeks after vaccination and
challenge to detect BCG or M. bovis excretion. The presence of
BCG excreted per pen/treatment group was also measured in
feces collected in the pens for 2 weeks after vaccination.
All samples were cultured on the day of collection, except
for rectal swabs and feces that were stored at 2–8◦C in saline
solution and then cultured on the following working day. The
laryngeal swab and tracheal aspirate were agitated in 7H9 broth
and then cultured on six modified Middlebrook 7H11 slopes
containing OADC enrichment (BD) and incubated for 12 weeks
at 37◦C. After challenge, when samples could contain both BCG
and M. bovis, two additional plates of solid Middlebrook 7H11
medium containing OADC and 60 µg/ml cycloserine; the latter
to select for BCG growth (Rist et al., 1967; Grange et al., 1996),
were also used per sample. Except for fecal swabs and feces, the
samples were not decontaminated before culture. Faecal swabs
and feces samples were dispersed in 0.85% (w/v) saline solution.
The following working day the swab was discarded and the saline
solution decontaminated with 5% (v/v) final volume ethanedioic
acid (oxalic acid) for 20–30 min at room temperature. The oxalic
acid was removed by a wash step using saline and material for
sowing was retrieved by centrifugation.
Tissue samples collected at post-mortem were collected
aseptically, weighed and frozen at −20◦C. The following tissues
were sampled: left and right lung lobes (cranial, caudal, middle,
accessory); LNs, left and right where appropriate (anterior and
posterior mediastinals, left and right bronchial, mandibular,
parotid, retropharyngeal, axillary, inguinal, popliteal, hepatic,
mesenteric); tonsils; mediastinal pleura; spleen; liver; heart; and
kidneys. Tissues for culture were thawed at room temperature
and each tissue sample was cultured separately except for pooled
left and right axillary LN, pooled left and right inguinal LN and
pooled left and right popliteal LN. Left and right kidneys were
also cultured together. Tissues were homogenized in 10 ml 0.85%
(w/v) saline using IKA R© DT-Tubes (IKA R© Werke GmbH & Co.
KG, Staufen, Germany) and a 100 µl of homogenate spread onto
each culture plate. If contamination occurred, stored homogenate
was re-cultured. Up to 20 colonies from one plate per tissue
were typed by spoligotyping (Kamerbeek et al., 1997) and VNTR
(Frothingham and Meeker-O’connell, 1998) to confirm that the
isolates were the same as the challenge strain.
Immunological Assays
The immune responses were monitored by measuring the
frequency of peripheral blood mononuclear cells (PBMC)
producing IFNγ by ELISPOT assay (Lesellier et al., 2006), and
by measuring the presence of specific antibodies in serum
against a mixture ofM. tuberculosis Complex antigens, including
MPB83, using the Brock TB Stat-Pak test (Chambers et al.,
2008). Antigens used to stimulate PBMC cultures were PPD-B
(Weybridge antigen) and a cocktail of ESAT-6 and CFP-10 (kind
gift of M. Singh, Lionex GmbH, Braunschweig, Germany).
Post-mortem Examination
All badgers were killed humanely with an intravenous overdose
of sodium pentobarbitone 12 weeks after challenge with M.
bovis and promptly subjected to post-mortem examination.
Experience of this challenge model has shown that TB lesions
have developed by this point but clinical signs of TB have
not. During collection of tissues and organs their surface was
examined for visible lesions. After collection lymph nodes (LNs)
and organs (except lung) were sliced for examination of their
internal structures. The surfaces of the lung were examined at
collection, before samples were taken from the lung lobes for
culture. At this point, the rest of the lung was immersed in
formalin using a 1/10 (v/v) tissue/fixative ratio. The trachea was
opened to ensure the lungs were in contact with formalin during
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the fixation. Paper towels were placed on top of the organ to
avoid unfixed tissue due to floating. After 1 week of fixation in
buffered formalin, the lungs were finely sliced. Samples of fresh
tissues were collected for histopathology and culture. For large
organs, such as spleen, approximately 3× 3× 3 cm of tissue was
submitted for culture and a similar volume for histology. A visible
lesion score was derived using a standardized ordinal scoring
system from 0 no lesions, 1 (few foci or slight enlargement of the
LN) through to 4 (extensive caseation or areas of coalesced foci)
(Corner et al., 2007; Crawshaw et al., 2008). Only visible lesions
in organs and LNs from which M. bovis was isolated by culture
or were found to contain acid-fast bacilli (AFB) in Ziehl-Neelsen
(ZN) stained histological sections counted toward the final score.
The final visible lesion score was derived from the sum of the
highest scoring lung lobe plus the scores from all other organs
and LNs.
Histopathology
Granulomas were scored for their severity or degree of
maturation from 1 to 4. Those given a score of 1 contained
lymphocytes, epithelioid and plasma cells. Those given a score
of 4 were considered the most severe lesions with caseation
and mineralization present. Tissue sections with active lymphoid
follicles only, commonly seen in lymph nodes and spleen, were
scored as 0 and therefore were not included in the calculation
of final scores. More developed granulomas may be characterized
by greater deposition of collagen within or around the granuloma
(Wangoo et al., 2005). Collagen was visualized by Martius Scarlet
Blue (MSB) staining, and its abundance scored from 0 to 2. The
score was allocated from the most severe lesion observed on the
section. Final scores for each animal were calculated as a sum of
the individual tissue scores for granuloma and collagen. Scores
were not included for a tissue from which M. bovis was neither
cultured nor AFB present histologically.
Data Analysis
Raw data were entered into a Microsoft Access database by
operatives blinded to the treatment each badger had received.
The treatment allocations were revealed only when all data had
been entered and scores calculated. For each study, analysis
of disease severity scores, the number of tissues with visible
lesions and histopathology lesions were conducted using the non-
parametric Kruskal Wallis test. Significant differences between
treatment-groups within each study were investigated further
using Dunn’s test for multiple pair wise comparisons, vaccination
against control. Culture data were continuous and normally
distributed and analyzed by parametric one-way ANOVA and
investigated further using Sidak’s multiple comparison post-test.
Statistically significant differences (p < 0.05) are denoted in the
figures as a bar. All other statistical analyses are described in
context.
RESULTS
One VES4 badger vaccinated with LD BCG-LiporaleTM died
under anesthesia 4 weeks after challenge and was excluded
from the assessment of that study. This badger did not
present any pathological clinical sign and its weight and rectal
temperature (12 kg and 39.6◦C, respectively) were within the
10–90% percentile of the group.
Tuberculous Lesions Post-mortem
Only two badgers had no visible lesions, one vaccinated with HD
BCG-LiporaleTM in VES3 (Figure 1A) and the other vaccinated
with LD BCG-LiporaleTM in VES4 (Figure 1B). In most animals
with visible lesions, the right lung and draining LNs (either the
right tracheobronchial or the posterior mediastinal) contained
the most severe lesions, which is consistent with the route of
experimental infection. The most frequently affected LN outside
of the thoracic cavity was the hepatic LN. No lesions were found
in the kidneys of any animal, althoughM. boviswas isolated from
the kidneys of one control animal in VES4 and from a CB-BCG
vaccinated animal in VES3. In neither case wasM. bovis isolated
from the urine.
The sum of the visible lesion scores, a measure of disease
severity, for each animal is shown in Figure 1. Control animals
had a median score of 13 (range, 10–15) in VES3 (Figure 1A)
and 12 (range, 8–18) in VES4 (Figure 1B), demonstrating
the consistency of the challenge model despite these being
outbred animals. Analysis of the accumulated visible lesion scores
revealed a significant reduction in the median score for badgers
vaccinated with HD BCG-LiporaleTM (3) compared with controls
in VES3 (13). The CB-BCG vaccine reduced the median lesion
score to 7.5 and whilst this suggested a protective effect, the
difference was not significant.
In VES4, the median lesion severity score for LD BCG-
LiporaleTM (5) was less than the controls (12) but the difference
was not statistically significant. The median for HD BCG-
LiporaleTM of 13.5 was higher than the controls but the difference
was not significant.
Histopathology
Three measures of disease severity using histopathological
characteristics are shown for each animal in Figure 2. Consistent
with the results for visible lesion scores, HD BCG-LiporaleTM
vaccination in VES3 significantly reduced the number of
sites with histological lesions (Figure 2A), the severity of
granulomas (Figure 2C), as well as degree of collagen deposition
(Figure 2E). Vaccination with CB-BCG also significantly reduced
the severity of granulomas (Figure 2C) as well as the degree
of collagen deposition (Figure 2E). In VES4, in all three
histological measures of severity (Figures 2B,D,F) the LD BCG-
LiporaleTM group had lower median scores than the control
but these differences were not significant. In VES4, the HD
BCG-LiporaleTM vaccinates had higher median granuloma and
collagen scores than the controls but the differences were not
significant.
Distribution of M. bovis Infection
The M. bovis challenge strain was the only wild-type strain
recovered from badgers in these studies. The total number of sites
affected by M. bovis on the basis of confirmed visible lesions is
shown for each animal in Figure 3, along with sites of thoracic
and extra-thoracic infection. In the control groups the median
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FIGURE 1 | Vaccination of badgers with BCG and challenged 13 weeks later with endobronchial M. bovis. Lesion scores at post-mortem (12 weeks
post-challenge) in VES3 (A) and VES4 (B). Individual animal results are shown together with the group median. Badgers were vaccinated with either CB-BCG () or
HD BCG-LiporaleTM vaccine [denoted by the (N)] or LD BCG-LiporaleTM vaccine [denoted by the delta symbol (H)]. LiporaleTM alone was used as a negative control
for vaccination (•). A significant difference according to Dunn’s test for multiple pair wise comparisons is shown by the bar.
numbers of infected sites were 8.5 and 9.5 for VES3 and VES4,
respectively (Figures 3A,B), i.e., approximately a third of all
the organs/tissues examined. Only vaccination with HD BCG-
LiporaleTM in VES3 reduced this significantly to a median of four
sites.
Vaccination altered the distribution of infection. In VES3, the
number of sites infected in total, and separately in the thoracic
cavity and extra-thoracic sites, were fewer after vaccination with
both HD BCG-LiporaleTM and CB-BCG than in the controls.
However, the differences were only significant in the comparison
between HD BCG-LiporaleTM and the controls. In VES4, the
number of sites infected in total, and separately in the thoracic
cavity and extra-thoracic sites, were fewer after vaccination
with LD BCG-LiporaleTM than in the controls, although none
of these differences were significant. In all control animals,
M. bovis had disseminated from the lung, where it had been
deposited, to extra-thoracic sites; with a range of 1–9 sites affected
(Figures 3E,F). In contrast, in both studies vaccination with
BCG-LiporaleTM, both LD and HD, reduced the dissemination
of M. bovis from the lung to other organs, such that we were
unable to detect M. bovis in any of the extra-thoracic sites
in 6/8 animals vaccinated with HD BCG-LiporaleTM in VES3
(Figure 3E) and 4/7 animals vaccinated with LD BCG-LiporaleTM
in VES4 (Figure 3F). These proportions were significantly lower
than the controls in both studies (Fisher’s Exact test).
Bacteriology
Mycobacterium bovis was cultured from organs and tissues with
macroscopic lesions and from tissues with only microscopic
lesions, and also from organs and tissues without lesions (data
not shown). M. bovis was isolated intermittently from clinical
samples taken from animals after challenge. There were no
significant differences between treatment groups in these respects
(data not shown). No urine sample was positive.
Bacillus Calmette-Guérin (BCG) was only isolated from
clinical samples twice and only in VES3 and from the same
two badgers, both vaccinated with BCG-LiporaleTM. The isolates
were from a laryngeal swab 2 weeks after vaccination and
from a tracheal aspirate 4 weeks after vaccination. BCG was
not isolated from feces collected from the animal pens. Post-
mortem, BCG was isolated from the left retropharyngeal LN
of one badger and from the right retropharyngeal LN of
another, vaccinated 25 weeks previously with CB-BCG and BCG-
LiporaleTM, respectively, in VES3.
Immunology
In VES3 and VES4, an IFNγ response to PPD-B was detected by
ELISPOT in all badgers after vaccination and in all badgers after
challenge (Figures 4A,C). In VES3, responses to PPD-Bwere also
seen in control animals prior to challenge (Figure 4A). In VES4,
background responses of control animals to PPD-Bwere very low
and there was a significantly greater response to PPD-B in those
badgers receiving HD BCG-LiporaleTM compared to LD BCG-
LiporaleTM 4 weeks after vaccination (Figure 4C), but at no other
time point.
Vaccinated animals before challenge did not respond to
a combination of ESAT-6 and CFP-10 antigens, consistent
with the absence of genes encoding these antigens from BCG
(Figures 4B,D). There was one exception, a single animal within
the LiporaleTM group that had a marginally elevated response to
ESAT-6 and CFP-10 on day 7 before vaccination. However, the
mean result for this group was statistically indistinguishable from
the other treatment groups and an elevated response was not seen
again at any other time point prior to challenge in this animal.
In VES3, the peak mean response to ESAT-6/CFP-10 was seen
5 weeks after challenge in both the control and two vaccinated
groups. In VES4, the peak mean response to ESAT-6/CFP-10
was seen 7 weeks after challenge in the control and HD BCG-
LiporaleTM groups but at 4 weeks in the LD BCG-LiporaleTM
group. In all cases, the level of IFNγ production correlated poorly
with disease severity (data not shown).
In VES3, vaccination with HD BCG-LiporaleTM resulted
in significantly fewer Stat-Pak positive badgers after challenge
compared with the other groups (p = 0.0235, Chi-square test)
and vaccination caused a significant delay to the seroconversion
of those that did become positive (p = 0.008, Log-rank test)
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 January 2017 | Volume 7 | Article 6
Chambers et al. Oral BCG Vaccination of Badgers
FIGURE 2 | Vaccination of badgers with BCG and challenged 13 weeks later with endobronchial M. bovis. Histopathology assessment. Number of sites
with histological lesions (A,B), scores for granuloma severity (C,D) and collagen (E,F) in VES3 (left panel) and VES4 (right panel). Individual animal results are shown
together with the group median. Badgers were vaccinated with either CB-BCG (), HD BCG-LiporaleTM (N) or LD BCG-LiporaleTM vaccine (H). LiporaleTM alone was
used as a negative control for vaccination (•). A significant difference according to Dunn’s test for multiple pair wise comparisons is shown by the bar.
(Figure 5A). In VES4, vaccination with BCG-LiporaleTM at either
dose did not result in significantly fewer Stat-Pak positive badgers
after challenge compared with the controls. Although the median
time taken to seroconversion after challenge was 4 weeks in the
case of controls and delayed to 8.5 and 10 weeks for high and
low dose vaccination groups, respectively, these differences were
not significant (Log-rank test) (Figure 5B). One VES4 control
animal was reactive in the Brock TB Stat-Pak for the duration
of the study (data not shown). This animal had low PPD-
B responses pre-challenge but no response to ESAT-6/CFP-10
pre-challenge, and the severity of TB post-mortem was typical
of the group, suggesting it was genuinely uninfected at the
start of the study. No other badger was seropositive before
vaccination. One HD BCG-LiporaleTM vaccinated animal (in
VES3) became reactive in the Stat-Pak 7 weeks after vaccination
and remained so for the duration of the experiment (data not
shown).
DISCUSSION
In both studies we demonstrated considerable levels of protection
against the development of tuberculosis in badgers vaccinated
with BCG. However, there was a surprising result: the high dose
of BCG was protective in the first but not the second study,
whereas the low dose of BCG was protective in the latter.
We assessed the severity of disease in our experimental
challenge model using a combination of visible pathology
(number and severity of visible lesions expressed as a total Visible
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FIGURE 3 | Vaccination of badgers with BCG and challenged 13 weeks later with endobronchial M. bovis. Number of organs/tissues from which M. bovis
was isolated or AFB found 12 weeks post-challenge for VES3 (left panel) and VES4 (right panel). The total number of affected tissues is shown (A,B), together with
their distribution: thoracic (C,D) or extra-thoracic (E,F). Individual animal results are shown together with the group median. Badgers were vaccinated with either
CB-BCG (), HD BCG-LiporaleTM (N) or LD BCG-LiporaleTM vaccine (H). LiporaleTM alone was used as a negative control for vaccination (•). A significant difference
according to Dunn’s test for multiple pair wise comparisons is shown by the bar.
Lesion Score), histopathology (granuloma severity, collagen
abundance), and dissemination of M. bovis (by culture and
histopathology) and the excretion of M. bovis. In VES3, the
oral administration of 1.86 × 108 CFU BCG in LiporaleTM gave
statistically significant protection in every measure used to assess
vaccine efficacy, with the exception that it did not significantly
reduce the frequency of M. bovis excretion by badgers or the
bacterial load per gram of tissue submitted for bacteriology. For
all the measures of gross disease, the CB-BCG vaccine resulted
in less severity than the controls. For both of the histological
measures (granuloma severity and collagen deposition) these
reductions were statistically significant. Due to the small
number of badgers used in the CB-BCG group, statistical
significance was not demonstrated in the number of tissues
infected.
In VES4 there was the unexpected result that the lower dose
was more protective than the higher dose. Although in the HD
BCG-LiporaleTM group there were three parameters with better
results than the controls, the differences were not significant
statistically. One explanation for this is the small number of
badgers used (n = 4), exacerbated by the variability of the
response within each of the groups. Indeed there appeared to
be greater variation in the disease parameters seen in the control
group of VES4 compared with the control group of VES3. Whilst
this is nothing beyond which we have seen previously in this
model, it does illustrate the difficult in conducting experimental
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FIGURE 4 | Vaccination of badgers with BCG and challenged 13 weeks later with endobronchial M. bovis: IFNγ ELISPOT results from experiment VES3
(A,B) and VES4 (C,D) expressed as the net spot forming cells (SFC) per million cells in response to stimulation with PPD-B (A,C) or ESAT-6/CFP-10 (B,D).
FIGURE 5 | Vaccination of badgers with BCG and challenged 13 weeks later with endobronchial M. bovis: Proportion of each treatment group positive
in the Brock TB Stat-Pak serological test after challenge with M. bovis from experiments VES3 (A) and VES4 (B). Badgers were vaccinated with either
CB-BCG (), HD BCG-LiporaleTM (N) or LD BCG-LiporaleTM vaccine (H). LiporaleTM alone was used as a negative control for vaccination (•).
efficacy studies using outbred animals where there is a practical
constraint on group sizes, as is the case here. Nonetheless, it
is still clear, not only from the disease severity score but from
additional measures, that BCG vaccination altered the expression
and progression of experimental infection. There was evidence in
both studies that BCG in LiporaleTM was able to restrict the ability
ofM. bovis to disseminate from the thoracic cavity, the initial site
of infection, even if it didn’t apparently reduce the bacterial load
within the tissue samples. These results are in general agreement
with the protection seen in two earlier assessments of oral BCG
in the same lipid matrix (Corner et al., 2010; Murphy et al., 2014)
where the impact on bacterial load was minimal. Excretion of
M. bovis was intermittent in both studies, and the impact of
vaccination on this measure is less clear than in earlier studies
when injectable vaccination was performed (Lesellier et al., 2011).
Failure of oral BCG to reduce the apparent bacterial load
or excretion in the badger challenge model could be an artifact
of the model in which the M. bovis challenge dose is likely
to be higher than encountered in natural infection. Both for
experimental and natural infection, excretion of M. bovis is
highly intermittent (Chambers et al., 2002; Lesellier et al., 2011).
Furthermore, the quantification of M. bovis in tissues is only
semi-quantitative at best since counts were either derived either
from the majority of the organ (e.g., in the case of lymph nodes)
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or a far smaller proportion of the organ (e.g., spleen). It remains
the case, however, that at the doses of BCG used in these studies
and/or the method of delivery that the efficacy of the vaccine
does not extend to reducing bacterial load. Whether this will
ultimately reduce the efficacy of oral vaccination in the field will
need to be determined once the minimum efficacious dose of
oral BCG has been established experimentally.Whilst a reduction
in bacterial load through vaccination would be ideal it might
not be essential to prevent onward transmission of infection;
which is a combination of bacterial load and the opportunity
afforded for excretion by tissue location and pathology.We found
previously, through thorough histopathological examination of
naturally-infected badgers, that both mildly and severely infected
badgers have the potential to excrete M. bovis by several routes
(Gavier-Widen et al., 2001).
All animals responded in the IFNγ ELISPOT after they
were challenged with M. bovis. Responses to ESAT-6/CFP-
10 antigens were seen after challenge but the level of IFNγ
production correlated poorly with disease severity. The same
poor association has been found in cattle (Vordermeier et al.,
2002), and in a previous badger study with oral BCG (Murphy
et al., 2014). In VES3, responses to PPD-B in the ELISPOT
assay were seen in control animals prior to challenge. As the
response of all animals from all treatment groups in VES3
had higher responses to PPD-A by ELISPOT in the run up
to challenge (data not shown), we conclude from this that the
PPD-B responses were most likely a cross-reaction to exposure
with Mycobacterium avium from the environment. As birds
have access the pens in which the badgers are housed prior to
challenge, there is opportunity for this to occur. As prior to
challenge no responses were seen in these animals to ESAT-
6/CFP-10 and M. bovis was not isolated from clinical samples,
we are confident that none of the VES3 animals were harboring
TB prior to challenge.
We also examined the impact of oral BCG on the serological
response of badgers to infection. Vaccination with HD BCG-
LiporaleTM in VES3 reduced the extent of seroconversion after
challenge, consistent with previous observations for BCG given
subcutaneously (Lesellier et al., 2009), but not for BCG given
intramuscularly (Lesellier, unpublished results). In VES4, a
reduction in the extent of seroconversion was not observed
following vaccination with BCG-LiporaleTM at either dose. One
VES4 control animal was reactive in the Brock TB Stat-Pak for the
duration of the study. Importantly, this animal was consistently
negative by IFNγ and culture before enrolment in the study and
noM. bovis, other than the challenge strain, was isolated from this
animal. We therefore conclude the sero-reactivity of this animal
was non-specific, possibly due to infection with environmental
mycobacteria with cross-reacting antigens.
BCG was not cultured from the feces collected from the
animal pens after vaccination in either experiment. This differed
from a previous study in which BCG was recovered infrequently
(on three occasions; three and 17 days after vaccination) from
the feces of badgers vaccinated with 108 CFU (Corner et al.,
2010) but in low concentrations (≤20 CFU/g feces). That is,
following oral vaccination with BCG either un-encapsulated
or encapsulated in lipid, excretion from the alimentary tract
occurs at low frequency and low quantity. This low or absence
of excretion indicates either very efficient uptake of BCG by
mucosal-associated lymphoid tissue (MALT) or a substantial
loss of BCG viability as it transits the gastrointestinal tract. To
understand these processes better, we are conducting studies
to evaluate BCG survival in an artificial gut that simulates the
conditions of the badger stomach and small intestine, along with
in vivo studies to evaluate the uptake of orally administered BCG
from the proximal and distal parts of the alimentary tract of
badgers. Although BCG encapsulated in lipid has previously been
shown to extend the survival of BCG in vivo (Aldwell et al.,
2006), the persistence of BCG in organs/tissues or BCG excretion
was apparently not associated with enhanced protection in our
studies.
We sought an explanation for the difference in the efficacy of
HD BCG-LiporaleTM in VES3 and the low dose in VES4 which
were protective and the unexpectedly poorer performance of
the high dose in VES4. It is possible that differences between
the protection induced by HD BCG-LiporaleTM in VES3 and
VES4 is simply a consequence of the small number of animals
in the VES4 group (n = 4). Whilst it is clear oral vaccination
with BCG can be highly efficacious, it may be inherently more
variable in its efficacy than when administered parentally. The
high dose of vaccine in both studies was biologically equivalent
and the experimental infections very similar based on disease in
the control groups, so these results may have been a matter of
chance resulting from the small group size.
It has been assumed that the most significant contribution
of the lipid matrix is to protect BCG from inactivation in the
stomach and to enhance the uptake of viable BCG from the
small intestine (Aldwell et al., 2006). Consistent with this, the
ISL lipid formulation has been demonstrated to confer protection
superior to unformulated oral BCG in guinea pigs (Clark et al.,
2008; Vipond et al., 2008) and possums (Aldwell et al., 2003).
However, the results presented here, and data we have generated
from guinea pig studies in which BCG administered orally
in LiporaleTM was recovered from cervical LNs (Clark et al.,
2008), suggest that oropharyngeal uptake of orally-presented
BCG may be important for stimulating protective immunity.
Evidence for a protective effect of the un-encapsulated CB-MSG
in VES3 suggests this may be the case. Although CB-BCG only
significantly reduced histological measures of disease severity, the
reduction in pathology was still encouraging given that we only
included four badgers in this group.
The objectives of the two (VES) reported here were to
compare the efficacy of BCG Danish strain in a lipid matrix with
unformulated BCG given orally and gain insights into the impact
that vaccine dose has on efficacy. We achieved those objectives.
Ultimately BCG will need to be delivered to wild badgers in bait
and we are making progress toward that objective (Robertson
et al., 2016). For the purposes of this study it was important that
we could control the dose of BCG each badger received so the
animals were dosed manually. In the wild it will not be possible
to control the amount of BCG each animal consumes and field
studies to evaluate this will be required before a product can be
licensed for use. At this point in time, further research is still
needed before we are able to recommend a final dose of BCG for
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oral vaccination of badgers against TB or to know whether oral
vaccination of wild badgers with BCG will significantly reduce
transmission of the disease.
CONCLUSIONS
The data presented here, together with previous reports
(Corner et al., 2010; Murphy et al., 2014), demonstrate that
the oral administration of BCG in ISL LiporaleTM matrix
significantly reduced the extent of tuberculous lesions following
intrabronchial M. bovis challenge. The challenge dose used
is likely to be higher than that which occurs during natural
exposure to infection. Our experimental challenge is a more
stringent test of vaccine efficacy than might be encountered
naturally.
AUTHOR CONTRIBUTIONS
MC and SL designed and drafted the work, and with assistance
from LC, analyzed and interpreted the data. GW, SP, SG, RA,
DJD, DD, UW, FS, AN, AKN, TC, LC, and SL conducted the
work. GW, SP, SG, RA, DJD, DD, UW, FS, AN, AKN, TC, and LC
assisted MC with drafting the work. All authors were involved in
critical review of the work, gave their final approval of the version
to be published, and agree to be accountable for all aspects of
the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated
and resolved. MC is Professor of Veterinary Bacteriology, School
of Veterinary Medicine, Faculty of Health & Medical Sciences,
University of Surrey, United Kingdom where he is funded 0.4
through the Higher Education Funding Council for England
(HEFCE).
ACKNOWLEDGMENTS
This work was funded by the Department for Environment, Food
and Rural Affairs (Defra). The authors acknowledge the help
of: Hugh Simmons, Carol Long and Roger Coombes from the
Animal Services Unit, APHA for the daily care of the badgers;
the staff of the Department of Pathology, APHA, in particular
Julie Gough, Angela Richards and Ann Long; the Diagnostic
Laboratory for Mycobacteria for the culture work, in particular
Jemma Brown, Keith Jahans and Jackie Brewer; Stephen Powell
for the development and maintenance of the database; and the
expertise of the staff based at Woodchester Park for the trapping
of the animals, in particular Paul Spyvee and Chris Hanks.
REFERENCES
Aldwell, F. E., Cross, M. L., Fitzpatrick, C. E., Lambeth, M. R., De Lisle, G. W.,
and Buddle, B. M. (2006). Oral delivery of lipid-encapsulated Mycobacterium
bovis BCG extends survival of the bacillus in vivo and induces a long-
term protective immune response against tuberculosis. Vaccine 24, 2071–2078.
doi: 10.1016/j.vaccine.2005.11.017
Aldwell, F. E., Keen, D. L., Parlane, N. A., Skinner, M. A., De Lisle, G. W., and
Buddle, B.M. (2003). Oral vaccination withMycobacterium bovisBCG in a lipid
formulation induces resistance to pulmonary tuberculosis in brushtail possums.
Vaccine 22, 70–76. doi: 10.1016/S0264-410X(03)00539-5
Beltrán-Beck, B., Romero, B., Sevilla, I. A., Barasona, J. A., Garrido, J. M.,
González-Barrio, D., et al. (2014). Assessment of an oral Mycobacterium bovis
BCG vaccine and an inactivated M. bovis preparation for wild boar in terms
of adverse reactions, vaccine strain survival, and uptake by nontarget species.
Clin. Vaccine Immunol. 21, 12–20. doi: 10.1128/CVI.00488-13
Brooks-Pollock, E., Roberts, G. O., and Keeling, M. J. (2014). A dynamic model of
bovine tuberculosis spread and control in Great Britain. Nature 511, 228–231.
doi: 10.1038/nature13529
Buddle, B. M., Hewinson, R. G., Vordermeier, H. M., and Wedlock, D. N. (2013).
Subcutaneous administration of a 10-fold-lower dose of a commercial human
tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin Danish,
induced levels of protection against bovine tuberculosis and responses in the
tuberculin intradermal test similar to those induced by a standard cattle dose.
Clin. Vaccine Immunol. 20, 1559–1562. doi: 10.1128/CVI.00435-13
Chambers, M. A., Pressling, W. A., Cheeseman, C. L., Clifton-Hadley, R.
S., and Hewinson, R. G. (2002). Value of existing serological tests for
identifying badgers that shedMycobacterium bovis.Vet. Microbiol. 86, 183–189.
doi: 10.1016/S0378-1135(02)00012-3
Chambers, M. A., Crawshaw, T., Waterhouse, S., Delahay, R. G., Hewinson, R.,
and Lyashchenko, K. P. (2008). Validation of the brocktb stat-pak assay for
detection of tuberculosis in Eurasian badgers (Meles meles) and influence
of disease severity on diagnostic accuracy. J. Clin. Microbiol. 46, 1498–1500.
doi: 10.1128/JCM.02117-07
Clark, S., Cross, M., Nadian, A., Vipond, J., Court, P., Williams, A., et al.
(2008). Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus
Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection
with virulent M. bovis. Infect. Immun. 76, 3771–3776. doi: 10.1128/IAI.
00052-08
Corner, L. A. L., Costello, E., Lesellier, S., O’meara, D., Sleeman, D. P., and
Gormley, E. (2007). Experimental tuberculosis in the european badger (Meles
meles) after endobronchial inoculation of Mycobacterium bovis: I. Pathology
and bacteriology. Res. Vet. Sci. 83, 53–62. doi: 10.1016/j.rvsc.2006.10.016
Corner, L. A., Costello, E., O’meara, D., Lesellier, S., Aldwell, F., Singh, M., et al.
(2010). Oral vaccination of badgers (Meles meles) with BCG and protective
immunity against endobronchial challenge withMycobacterium bovis. Vaccine
28, 6265–6272. doi: 10.1016/j.vaccine.2010.06.120
Crawshaw, T. R., Griffiths, I. B., and Clifton-Hadley, R. S. (2008). Comparison
of a standard and a detailed post-mortem protocol for detecting
Mycobacterium bovis in badgers. Vet. Rec. 163, 473–477. doi: 10.1136/vr.163.
16.473
Davison, K. E., Hughes, J. M., Gormley, E., Lesellier, S., Costello, E., and Corner,
L. A. (2007). Evaluation of the anaesthetic effects of combinations of ketamine,
medetomidine, romifidine and butorphanol in European badgers (Meles meles).
Vet. Anaesth. Analg. 34, 394–402. doi: 10.1111/j.1467-2995.2006.00339.x
Enticott, G., Maye, D., Ilbery, B., Fisher, R., and Kirwan, J. (2012). Farmers’
confidence in vaccinating badgers against bovine tuberculosis. Vet. Rec. 170,
204. doi: 10.1136/vr.100079
Frothingham, R., and Meeker-O’connell, W. A. (1998). Genetic diversity
in the Mycobacterium tuberculosis complex based on variable
numbers of tandem DNA repeats. Microbiology 144(Pt 5), 1189–1196.
doi: 10.1099/00221287-144-5-1189
Gallagher, J., and Horwill, D. M. (1977). A selective oleic acid albumin agar
medium for the cultivation ofMycobacterium bovis. J. Hyg. (Lond). 79, 155–160.
doi: 10.1017/S0022172400052943
Gavier-Widen, D., Chambers, M. A., Palmer, N., Newell, D. G., and Hewinson,
R. G. (2001). Pathology of natural Mycobacterium bovis infection in European
badgers (Meles meles) and its relationship with bacterial excretion.Vet. Rec. 148,
299–304. doi: 10.1136/vr.148.10.299
Grange, J. M., Yates, M. D., and De Kantor, I. N. (1996). Guidelines for
Speciation with in the Mycobacterium tuberculosis Complex. 2nd, Edn.
WHO/EMC/ZOO/96.4. Geneva: World Health Organization.
Kamerbeek, J., Schouls, L., Kolk, A., Van Agterveld, M., Van Soolingen, D.,
Kuijper, S., et al. (1997). Simultaneous detection and strain differentiation of
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 January 2017 | Volume 7 | Article 6
Chambers et al. Oral BCG Vaccination of Badgers
Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin.Microbiol.
35, 907–914.
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., and Altman, D. G.
(2010). Improving bioscience research reporting: the ARRIVE guidelines for
reporting animal research. PLoS Biol. 8:e1000412. doi: 10.1371/journal.pbio.
1000412
Lesellier, S., Corner, L., Costello, E., Lyashchenko, K., Greenwald, R., Esfandiari,
J., et al. (2009). Immunological responses and protective immunity in BCG
vaccinated badgers following endobronchial infection with Mycobacterium
bovis. Vaccine 27, 402–409. doi: 10.1016/j.vaccine.2008.10.068
Lesellier, S., Palmer, S., Dalley, D. J., Davé, D., Johnson, L., Hewinson, R. G., et al.
(2006). The safety and immunogenicity of Bacillus Calmette-Guerin (BCG)
vaccine in European badgers (Meles meles). Vet. Immunol. Immunopathol. 112,
24–37. doi: 10.1016/j.vetimm.2006.03.009
Lesellier, S., Palmer, S., Gowtage-Sequiera, S., Ashford, R., Dalley, D., Davé, D., et al.
(2011). Protection of Eurasian badgers (Meles meles) from tuberculosis after
intra-muscular vaccination with different doses of BCG.Vaccine 29, 3782–3790.
doi: 10.1016/j.vaccine.2011.03.028
Murphy, D., Costello, E., Aldwell, F. E., Lesellier, S., Chambers, M. A., Fitzsimons,
T., et al. (2014). Oral vaccination of badgers (Meles meles) against tuberculosis:
comparison of the protection generated by BCG vaccine strains Pasteur and
Danish. Vet. J. 200, 362–367. doi: 10.1016/j.tvjl.2014.02.031
Rist, N., Canetti, G., Boisvert, H., and Le Lirzin, M. (1967). L’antibiogramme
du BCG. Valeur diagnostique de la resistance a la cycloserine. Rev. Tuberc.
Pneumonol. 31, 1060–1065.
Robertson, A., Delahay, R. J., McDonald, R. A., Aylett, P., Henderson, R., Gowtage,
S., et al. (2016). Behaviour of European badgers and non-target species towards
candidate baits for oral delivery of a tuberculosis vaccine. Prev. Vet. Med. 135,
95–101. doi: 10.1016/j.prevetmed.2016.11.007
University of Reading. (2004). Assessment of the Economic Impacts of TB and
Alternative-SE3112Control Policies. Defra Research Project final Report.
Vipond, J., Cross, M. L., Lambeth, M. R., Clark, S., Aldwell, F. E., and Williams,
A. (2008). Immunogenicity of orally-delivered lipid-formulated BCG vaccines
and protection against Mycobacterium tuberculosis infection. Microbes Infect.
10, 1577–1581. doi: 10.1016/j.micinf.2008.09.004
Vordermeier, H. M., Chambers, M. A., Cockle, P. J., Whelan, A. O.,
Simmons, J., and Hewinson, R. G. (2002). Correlation of ESAT-6-
specific gamma interferon production with pathology in cattle following
Mycobacterium bovis BCG vaccination against experimental bovine
tuberculosis. Infect. Immun. 70, 3026–3032. doi: 10.1128/IAI.70.6.3026-
3032.2002
Wangoo, A., Johnson, L., Gough, J., Ackbar, R., Inglut, S., Hicks, D., et al.
(2005). Advanced granulomatous lesions in Mycobacterium bovis-infected
cattle are associated with increased expression of type I procollagen,
gammadelta (WC1+) T cells and CD 68+ cells. J. Comp. Pathol. 133, 223–234.
doi: 10.1016/j.jcpa.2005.05.001
World Health Organization (1994).World Health Organization, Veterinary Public
Health Unit. Report of WHO/FAO/OIE consultation on animal tuberculosis,
WHO/CDS/VPH/94.138. Geneva.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
FA is Chief Scientist and Director of Immune Solutions Ltd, the company
that supplied the vaccine. Relevant patents derived by Immune Solutions from
PCT/NZ2002/000132, entitled “Antigenic compositions” are as follows. Granted
in Australia (2008202282), Canada (2,454,920), China (837462), India (235505),
Japan (4685350), New Zealand (562036), South Africa (2004/1211), and United
States (7,758,869). Pending in Europe (02760915, 10188891) and Hong Kong
(04109263.7).
Copyright © 2017 Chambers, Aldwell, Williams, Palmer, Gowtage, Ashford, Dalley,
Davé, Weyer, Salguero, Nunez, Nadian, Crawshaw, Corner and Lesellier. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12 January 2017 | Volume 7 | Article 6
